Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted EBITDA Margin of 1403.74% for Q1 2026, down 222.65% on a QoQ basis from 435.06% in Q4 2025, and down 134647.0% year-over-year from N/an in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' EBITDA Margin history runs 9 years deep, the most recent figure standing at 1403.74% for Q1 2026.
- Quarterly EBITDA Margin fell 134647.0% year-over-year to 1403.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 161.52% (down 10439.0% YoY) and the FY2025 annual result came in at 92.96%, down 3015.0% from the prior year.
- EBITDA Margin was 1403.74% for Q1 2026 at Arcturus Therapeutics Holdings, down from 435.06% in the prior quarter.
- Across five years, EBITDA Margin topped out at 75.77% in Q4 2022 and bottomed at 1403.74% in Q1 2026.
- A 5-year average of 245.88% and a median of 80.01% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 260313 bps — and 2026, when it slumped 134647 bps.
- Arcturus Therapeutics Holdings' EBITDA Margin stood at 75.77% in 2022, then tumbled by 178 bps to 59.22% in 2023, then sank by 148 bps to 146.68% in 2024, then plunged by 197 bps to 435.06% in 2025, then tumbled by 223 bps to 1403.74% in 2026.
- Business Quant data shows ARCT's EBITDA Margin at 1403.74% in Q1 2026, 435.06% in Q4 2025, and 96.27% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -1,403.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,403.74% |
| Dec 31, 2025 | -435.06% |
| Sep 30, 2025 | -96.27% |
| Jun 30, 2025 | -41.04% |
| Mar 31, 2025 | -57.27% |
| Dec 31, 2024 | -146.68% |
| Sep 30, 2024 | -25.76% |
| Jun 30, 2024 | -42.37% |
| Mar 31, 2024 | -80.01% |
| Dec 31, 2023 | -59.22% |
| Sep 30, 2023 | -42.79% |
| Jun 30, 2023 | -526.42% |
| Mar 31, 2023 | 18.38% |
| Dec 31, 2022 | 75.77% |
| Sep 30, 2022 | -275.32% |
| Jun 30, 2022 | -81.53% |
| Mar 31, 2022 | -960.70% |
| Dec 31, 2021 | -649.72% |
| Sep 30, 2021 | -2,208.49% |
| Jun 30, 2021 | -2,684.66% |